Attached files
| file | filename |
|---|---|
| EX-31.1 - Immune Therapeutics, Inc. | ex31-1.htm |
| EX-10.70 - Immune Therapeutics, Inc. | ex10-70.htm |
| EX-10.69 - Immune Therapeutics, Inc. | ex10-69.htm |
| EX-10.68 - Immune Therapeutics, Inc. | ex10-68.htm |
| EX-10.67 - Immune Therapeutics, Inc. | ex10-67.htm |
| EX-10.66 - Immune Therapeutics, Inc. | ex10-66.htm |
| 10-Q - Immune Therapeutics, Inc. | form10-q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
| In connection with the quarterly report of Immune Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I , Kevin J. Phelps, Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2020, that to the best of my knowledge: |
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.
| Date: May 24, 2021 | By: | /s/ Kevin J. Phelps |
| Kevin J. Phelps | ||
| Chief Executive Officer | ||
(Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) |